SMOFlipid®

Omega-3 fatty acids have proven benefits for adult hospitalised patients^1,2* Compared with standard PN†, hospitalised adults who received omega-3 fatty-acid enriched PN had a lower risk of infection, shorter ICU stay, shorter hospital stay and a lower sepsis risk: 

• 40% lower risk of infection (131 vs 215 events; RR 0.60, 95% CI  0.49–0.72; p<0.00001) - Co-primary endpoint
• Shorter ICU stay (Mean stay length reduced by 1.95 days, 95% CI  0.42–3.49; p=0.01)
• Shorter hospital stay (Mean stay length reduced by 2.14 days, 95% CI 1.36–2.93; p<0.00001)
• 56% lower risk of sepsis (24 vs 54 events; RR 0.44, 95% CI 0.28–0.70; p=0.0004)

*Systematic Systemic review and meta-analysis of 49 randomised, controlled trials (3641 ICU or surgical patients. For the outcomes of: infection rate, 24 studies, n=2154, ARR = 8%; 30-day mortality, 20 studies, n=1839, ARR = 2%; sepsis, 9 studies, n=1141, ARR = 6%; LOHS, 26 studies, n-2182; ICU stay, 10 studies, n=822).²
†non omega-3 fatty acid enriched.
ARR, Absolute Risk Reduction; CI, Confidence Interval; ICU, Intensive Care Unit; LOHS, length of hospital stay; NS, Not Significant; PN, Parenteral Nutrition; RR, Relative Risk.


​1. Calder PC, et al. Lipids in the intensive care unit: Recommendations from the ESPEN Expert Group. Clinical Nutrition. 2018;37(1):1–18
2. Pradelli L, et al. ω-3 fatty-acid enriched parenteral nutrition in hospitalized patients: Systematic review with meta-analysis and trial sequential analysis. Journal of Parenteral Enteral Nutrition. 2020;44(1):44–57.